Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
5.336
Zitationen
25
Autoren
2005
Jahr
Abstract
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)
Ähnliche Arbeiten
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
1987 · 11.673 Zit.
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 · 11.442 Zit.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · 11.429 Zit.
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 · 9.375 Zit.
Cell Signaling by Receptor Tyrosine Kinases
2010 · 7.800 Zit.
Autoren
- Edward H. Romond
- Edith A. Perez
- John Bryant
- Vera J. Suman
- Charles E. Geyer
- Nancy E. Davidson
- Elizabeth Tan-Chiu
- Silvana Martino
- Soonmyung Paik
- Peter A. Kaufman
- Sandra M. Swain
- Thomas M. Pisansky
- Louis Fehrenbacher
- Leila A. Kutteh
- Victor G. Vogel
- Daniel W. Visscher
- Greg Yothers
- Robert B. Jenkins
- Ann Brown
- Shaker R. Dakhil
- Eleftherios P. Mamounas
- Wilma L. Lingle
- Pamela Klein
- James N. Ingle
- Norman Wolmark
Institutionen
- NSABP Foundation(US)
- University of Kentucky(US)
- Jacksonville College(US)
- University of Pittsburgh(US)
- Mayo Clinic in Arizona(US)
- Sidney Kimmel Comprehensive Cancer Center(US)
- Johns Hopkins University(US)
- Kaiser Permanente Vallejo Medical Center(US)
- Hematology Oncology Associates(US)
- UPMC Hillman Cancer Center(US)
- Aultman Health Foundation(US)
- Allegheny General Hospital(US)